NCT03659149

Pharmacokinetics and Safety Profile of CKD-333

An Open-label, Randomized, Fasted, Single-dose, Three-way Crossover Study to Compare the Pharmacokinetics and Safety Between Administration of CKD-333 and Coadministration of CKD-330 and D086 in Healthy Male Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Compare the pharmacokinetic characteristics and safety between CKD-333 tablet and CKD-330, D086 combination

Detailed description

An open-label, randomized, fasted, single-dose, three-way crossover study to compare the pharmacokinetic characteristics and safety between administration of CKD-333 and coadministration of CKD-330 and D086 in healthy male adults

Conditions

• Hypertension
• Dyslipidemias

Interventions

Type	Name	Description
DRUG	CKD-333 formulation I	1 tablet administered before the breakfast(single-dose)
DRUG	CKD-333 formulation II	1 tablet administered before the breakfast(single-dose)
DRUG	CKD-330+D086	2 tablet administered before the breakfast(single-dose)

Timeline

• Start date: 2018-08-08
• Primary completion: 2018-10-05
• Completion: 2018-10-12
• First posted: 2018-09-06
• Last updated: 2018-10-31

Locations

1 site across 1 country: South Korea